Gene therapies border on the miraculous, transforming lives in a single shot. The treatments offer hope to millions around the world who live with genetic diseases, and could also help the fight against cancer and HIV. This year, four new gene therapies were approved—and there are thousands more clinical trials under way. But the path from miracles of science to miracles of medicine will not be easy. The Economist’s Natasha Loder explains the safety concerns and market challenges that must be overcome to make the genetic revolution possible. Alok Jha hosts.
For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.
Hosted on Acast. See acast.com/privacy for more information.